AstraZeneca has agreed to purchase Gracell Biotechnologies Inc for $1.2 billion. Cambridge, United Kingdom-based AstraZeneca was advised by Freshfields Bruckhaus Deringer and Maples Group. Gracell Biotechnologies, which is based in Suzhou, China, was represented by Cooley and Harney Westwood & Riegels.
Biotech & Pharmaceuticals
December 29, 2023, 6:18 PM